nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxazosin—ADRA2A—attention deficit hyperactivity disorder	0.772	1	CbGaD
Doxazosin—ORM1—saliva—attention deficit hyperactivity disorder	0.00896	0.132	CbGeAlD
Doxazosin—Donepezil—HRH3—attention deficit hyperactivity disorder	0.00587	0.669	CrCbGaD
Doxazosin—KCNH6—forebrain—attention deficit hyperactivity disorder	0.00468	0.0688	CbGeAlD
Doxazosin—KCNH7—nervous system—attention deficit hyperactivity disorder	0.00357	0.0524	CbGeAlD
Doxazosin—KCNH7—central nervous system—attention deficit hyperactivity disorder	0.00344	0.0504	CbGeAlD
Doxazosin—KCNH7—cerebellum—attention deficit hyperactivity disorder	0.00336	0.0493	CbGeAlD
Doxazosin—KCNH7—brain—attention deficit hyperactivity disorder	0.00273	0.04	CbGeAlD
Doxazosin—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.0026	0.0381	CbGeAlD
Doxazosin—KCNH6—nervous system—attention deficit hyperactivity disorder	0.00254	0.0373	CbGeAlD
Doxazosin—KCNH6—central nervous system—attention deficit hyperactivity disorder	0.00245	0.0359	CbGeAlD
Doxazosin—KCNH6—brain—attention deficit hyperactivity disorder	0.00194	0.0285	CbGeAlD
Doxazosin—Prazosin—ADRA2A—attention deficit hyperactivity disorder	0.00157	0.179	CrCbGaD
Doxazosin—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.00149	0.0219	CbGeAlD
Doxazosin—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.00144	0.0211	CbGeAlD
Doxazosin—KCNH2—forebrain—attention deficit hyperactivity disorder	0.00144	0.0211	CbGeAlD
Doxazosin—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.00141	0.0207	CbGeAlD
Doxazosin—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.00139	0.0204	CbGeAlD
Doxazosin—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.00136	0.0199	CbGeAlD
Doxazosin—Donepezil—HTR2A—attention deficit hyperactivity disorder	0.00134	0.153	CrCbGaD
Doxazosin—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.00126	0.0185	CbGeAlD
Doxazosin—KCNH2—cardiovascular system—attention deficit hyperactivity disorder	0.00122	0.0179	CbGeAlD
Doxazosin—ORM1—nervous system—attention deficit hyperactivity disorder	0.00116	0.017	CbGeAlD
Doxazosin—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.00113	0.0166	CbGeAlD
Doxazosin—ORM1—central nervous system—attention deficit hyperactivity disorder	0.00112	0.0164	CbGeAlD
Doxazosin—ADRA1B—brain—attention deficit hyperactivity disorder	0.0011	0.0162	CbGeAlD
Doxazosin—ADRA1D—brain—attention deficit hyperactivity disorder	0.00108	0.0158	CbGeAlD
Doxazosin—KCNH2—midbrain—attention deficit hyperactivity disorder	0.000951	0.014	CbGeAlD
Doxazosin—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000878	0.0129	CbGeAlD
Doxazosin—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000809	0.0119	CbGeAlD
Doxazosin—KCNH2—nervous system—attention deficit hyperactivity disorder	0.000781	0.0115	CbGeAlD
Doxazosin—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000779	0.0114	CbGeAlD
Doxazosin—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000761	0.0112	CbGeAlD
Doxazosin—KCNH2—central nervous system—attention deficit hyperactivity disorder	0.000752	0.011	CbGeAlD
Doxazosin—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000748	0.011	CbGeAlD
Doxazosin—KCNH2—cerebellum—attention deficit hyperactivity disorder	0.000735	0.0108	CbGeAlD
Doxazosin—ABCB1—forebrain—attention deficit hyperactivity disorder	0.000631	0.00927	CbGeAlD
Doxazosin—ADRA1A—brain—attention deficit hyperactivity disorder	0.000618	0.00908	CbGeAlD
Doxazosin—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000615	0.00903	CbGeAlD
Doxazosin—KCNH2—brain—attention deficit hyperactivity disorder	0.000597	0.00877	CbGeAlD
Doxazosin—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000592	0.0087	CbGeAlD
Doxazosin—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000579	0.0085	CbGeAlD
Doxazosin—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.000534	0.00784	CbGeAlD
Doxazosin—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000477	0.007	CbGeAlD
Doxazosin—ADRA2A—brain—attention deficit hyperactivity disorder	0.00047	0.0069	CbGeAlD
Doxazosin—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000459	0.00674	CbGeAlD
Doxazosin—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000448	0.00658	CbGeAlD
Doxazosin—ABCB1—midbrain—attention deficit hyperactivity disorder	0.000417	0.00612	CbGeAlD
Doxazosin—CYP2D6—brain—attention deficit hyperactivity disorder	0.000364	0.00535	CbGeAlD
Doxazosin—ABCB1—nervous system—attention deficit hyperactivity disorder	0.000343	0.00503	CbGeAlD
Doxazosin—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00033	0.00485	CbGeAlD
Doxazosin—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.000323	0.00474	CbGeAlD
Doxazosin—ABCB1—brain—attention deficit hyperactivity disorder	0.000262	0.00385	CbGeAlD
Doxazosin—ADRA2A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000127	0.000838	CbGpPWpGaD
Doxazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000126	0.000834	CbGpPWpGaD
Doxazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000126	0.000831	CbGpPWpGaD
Doxazosin—KCNH2—SIDS Susceptibility Pathways—EP300—attention deficit hyperactivity disorder	0.000125	0.000829	CbGpPWpGaD
Doxazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000124	0.000821	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000124	0.00082	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000124	0.000819	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000124	0.000818	CbGpPWpGaD
Doxazosin—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000123	0.000814	CbGpPWpGaD
Doxazosin—ADRA1B—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000122	0.000809	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000122	0.000804	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000121	0.000801	CbGpPWpGaD
Doxazosin—ADRA2A—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.00012	0.000794	CbGpPWpGaD
Doxazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00012	0.000793	CbGpPWpGaD
Doxazosin—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00012	0.000791	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.000117	0.000776	CbGpPWpGaD
Doxazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000117	0.000775	CbGpPWpGaD
Doxazosin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000117	0.000775	CbGpPWpGaD
Doxazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000116	0.000765	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.000115	0.000762	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000115	0.000761	CbGpPWpGaD
Doxazosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.000114	0.000753	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.000114	0.000753	CbGpPWpGaD
Doxazosin—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000114	0.000752	CbGpPWpGaD
Doxazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000114	0.000751	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000113	0.000745	CbGpPWpGaD
Doxazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000112	0.000738	CbGpPWpGaD
Doxazosin—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000111	0.000737	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00011	0.00073	CbGpPWpGaD
Doxazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00011	0.000729	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00011	0.000727	CbGpPWpGaD
Doxazosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000109	0.000723	CbGpPWpGaD
Doxazosin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000109	0.00072	CbGpPWpGaD
Doxazosin—ADRA1A—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.000109	0.000718	CbGpPWpGaD
Doxazosin—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000109	0.000718	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000108	0.000715	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.000106	0.000702	CbGpPWpGaD
Doxazosin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000106	0.000698	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.000103	0.000681	CbGpPWpGaD
Doxazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000103	0.000679	CbGpPWpGaD
Doxazosin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000102	0.000677	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000102	0.000675	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.000101	0.000667	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.000101	0.000665	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	9.92e-05	0.000656	CbGpPWpGaD
Doxazosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	9.76e-05	0.000645	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	9.74e-05	0.000644	CbGpPWpGaD
Doxazosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	9.71e-05	0.000642	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.6e-05	0.000635	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	9.57e-05	0.000633	CbGpPWpGaD
Doxazosin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	9.54e-05	0.000631	CbGpPWpGaD
Doxazosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	9.45e-05	0.000625	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	9.45e-05	0.000625	CbGpPWpGaD
Doxazosin—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	9.44e-05	0.000624	CbGpPWpGaD
Doxazosin—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	9.38e-05	0.00062	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	9.35e-05	0.000618	CbGpPWpGaD
Doxazosin—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	9.31e-05	0.000616	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	9.16e-05	0.000606	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	9.14e-05	0.000605	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	8.96e-05	0.000592	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.93e-05	0.00059	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	8.92e-05	0.00059	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	8.8e-05	0.000582	CbGpPWpGaD
Doxazosin—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	8.69e-05	0.000574	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.65e-05	0.000572	CbGpPWpGaD
Doxazosin—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	8.62e-05	0.00057	CbGpPWpGaD
Doxazosin—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	8.57e-05	0.000566	CbGpPWpGaD
Doxazosin—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	8.51e-05	0.000562	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	8.5e-05	0.000562	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	8.5e-05	0.000562	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	8.42e-05	0.000557	CbGpPWpGaD
Doxazosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	8.4e-05	0.000555	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	8.4e-05	0.000555	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	8.32e-05	0.00055	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	8.3e-05	0.000549	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	8.3e-05	0.000549	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	8.23e-05	0.000545	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	8.14e-05	0.000538	CbGpPWpGaD
Doxazosin—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	8.12e-05	0.000537	CbGpPWpGaD
Doxazosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	8.1e-05	0.000536	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.04e-05	0.000531	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.82e-05	0.000517	CbGpPWpGaD
Doxazosin—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	7.8e-05	0.000516	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	7.8e-05	0.000516	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	7.75e-05	0.000512	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	7.72e-05	0.00051	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	7.65e-05	0.000506	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	7.56e-05	0.0005	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	7.43e-05	0.000491	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	7.36e-05	0.000487	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.31e-05	0.000484	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.27e-05	0.000481	CbGpPWpGaD
Doxazosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.19e-05	0.000476	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.99e-05	0.000462	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	6.84e-05	0.000453	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.8e-05	0.000449	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	6.69e-05	0.000442	CbGpPWpGaD
Doxazosin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	6.68e-05	0.000442	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	6.65e-05	0.00044	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	6.63e-05	0.000438	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	6.52e-05	0.000431	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	6.52e-05	0.000431	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	6.44e-05	0.000426	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.43e-05	0.000425	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	6.39e-05	0.000423	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.35e-05	0.00042	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	6.22e-05	0.000411	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.21e-05	0.000411	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	6.17e-05	0.000408	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	6.11e-05	0.000404	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	6.02e-05	0.000398	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	6e-05	0.000396	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	5.92e-05	0.000391	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.84e-05	0.000386	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.77e-05	0.000382	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.71e-05	0.000378	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.68e-05	0.000376	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.64e-05	0.000373	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.55e-05	0.000367	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.52e-05	0.000365	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.5e-05	0.000364	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.48e-05	0.000362	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.45e-05	0.00036	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	5.44e-05	0.00036	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.43e-05	0.000359	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.41e-05	0.000358	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.41e-05	0.000358	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.34e-05	0.000353	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.31e-05	0.000351	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.31e-05	0.000351	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.24e-05	0.000346	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5.16e-05	0.000341	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.09e-05	0.000337	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.05e-05	0.000334	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.04e-05	0.000334	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5e-05	0.00033	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.98e-05	0.000329	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.93e-05	0.000326	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.91e-05	0.000325	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.91e-05	0.000324	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.89e-05	0.000323	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.85e-05	0.000321	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.81e-05	0.000318	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.8e-05	0.000318	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.74e-05	0.000314	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.71e-05	0.000312	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.69e-05	0.00031	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.58e-05	0.000303	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.58e-05	0.000303	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.56e-05	0.000301	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.54e-05	0.0003	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.52e-05	0.000299	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.52e-05	0.000299	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.47e-05	0.000295	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.44e-05	0.000293	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.42e-05	0.000292	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.41e-05	0.000292	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.38e-05	0.00029	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.36e-05	0.000288	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.31e-05	0.000285	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.26e-05	0.000282	CbGpPWpGaD
Doxazosin—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.2e-05	0.000278	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.12e-05	0.000273	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.11e-05	0.000272	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.01e-05	0.000265	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4e-05	0.000265	CbGpPWpGaD
Doxazosin—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	3.96e-05	0.000262	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.95e-05	0.000261	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.86e-05	0.000255	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.81e-05	0.000252	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.77e-05	0.000249	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	3.76e-05	0.000249	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.76e-05	0.000249	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.75e-05	0.000248	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.73e-05	0.000247	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	3.7e-05	0.000245	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.67e-05	0.000243	CbGpPWpGaD
Doxazosin—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	3.64e-05	0.00024	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.56e-05	0.000235	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.55e-05	0.000235	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.5e-05	0.000231	CbGpPWpGaD
Doxazosin—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.49e-05	0.00023	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.45e-05	0.000228	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.44e-05	0.000228	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.33e-05	0.00022	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.28e-05	0.000217	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.22e-05	0.000213	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.16e-05	0.000209	CbGpPWpGaD
Doxazosin—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.1e-05	0.000205	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.1e-05	0.000205	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.05e-05	0.000202	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.01e-05	0.000199	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.95e-05	0.000195	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.91e-05	0.000193	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.9e-05	0.000192	CbGpPWpGaD
Doxazosin—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.88e-05	0.00019	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.87e-05	0.000189	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.81e-05	0.000186	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.71e-05	0.000179	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.71e-05	0.000179	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.67e-05	0.000177	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	2.67e-05	0.000176	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.67e-05	0.000176	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	2.62e-05	0.000173	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.62e-05	0.000173	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.61e-05	0.000173	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	2.6e-05	0.000172	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.6e-05	0.000172	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.58e-05	0.00017	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	2.56e-05	0.000169	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.55e-05	0.000168	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.52e-05	0.000166	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	2.45e-05	0.000162	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.45e-05	0.000162	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.44e-05	0.000161	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.44e-05	0.000161	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	2.41e-05	0.00016	CbGpPWpGaD
Doxazosin—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	2.41e-05	0.000159	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.38e-05	0.000157	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.37e-05	0.000157	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.36e-05	0.000156	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	2.28e-05	0.000151	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	2.26e-05	0.00015	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.25e-05	0.000149	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.24e-05	0.000148	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.2e-05	0.000146	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.13e-05	0.000141	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.08e-05	0.000138	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.03e-05	0.000134	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.98e-05	0.000131	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.96e-05	0.00013	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.87e-05	0.000124	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	1.87e-05	0.000123	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.66e-05	0.00011	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	1.62e-05	0.000107	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	1.6e-05	0.000106	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	1.58e-05	0.000104	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	1.57e-05	0.000104	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	1.56e-05	0.000103	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.54e-05	0.000102	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	1.49e-05	9.82e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	1.47e-05	9.75e-05	CbGpPWpGaD
Doxazosin—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.19e-05	7.89e-05	CbGpPWpGaD
Doxazosin—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.9e-06	6.55e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	9.78e-06	6.46e-05	CbGpPWpGaD
Doxazosin—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.8e-06	5.82e-05	CbGpPWpGaD
Doxazosin—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.17e-06	5.41e-05	CbGpPWpGaD
Doxazosin—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	6.93e-06	4.58e-05	CbGpPWpGaD
Doxazosin—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	6.76e-06	4.47e-05	CbGpPWpGaD
Doxazosin—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	6.37e-06	4.21e-05	CbGpPWpGaD
